Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999536 | 1.00 | S1PR3 (0.53) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL4289099 | 1.00 | S1PR3 (0.53) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL31750821 | 0.88 | S1PR3 (0.50) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL1525501 | 0.87 | CACNA1B (0.45) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL1525609 | 0.87 | CACNA1B (0.45) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL1525465 | 0.87 | S1PR3 (0.52) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL1525463 | 0.87 | S1PR3 (0.52) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL1525552 | 0.87 | S1PR3 (0.52) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL8513252 | 0.86 | CTSS (0.52) | S1PR3CTSSCTSKPPARAPPARG | |
| SCHEMBL191986 | 0.86 | CTSS (0.52) | S1PR3CTSSCTSKPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20230279553-A1 | Method for Manufacturing Conductive Pattern-Provided Structure | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-09-07 | — | — | US | disclosed |
| EP-4234758-A1 | METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE | Asahi Kasei Kabushiki Kaisha (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-20230159538-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-115989341-A | Method for manufacturing structure with conductive pattern | 旭化成株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-115968113-A | Method for manufacturing structure with conductive pattern, kit and system | 旭化成株式会社 | 2023-04-14 | — | — | CN | disclosed |
| EP-4126876-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | Global Blood Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022085461-A1 | METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE | 旭化成株式会社 | 2022-04-28 | — | — | WO | disclosed |
| WO-2021202796-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-2760845-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049250-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049250-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20110060146-A1 | VITAMIN-D-LIKE COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110060146-A1 | VITAMIN-D-LIKE COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20090137609-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137609-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137609-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2009005671-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1894911-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137609-A1 | VITAMIN D-LIKE COMPOUND | VDR, CYP24A1, CYP2R1 | S1PR3 277/4885CTSS 1699/4885CTSK 885/4885 |
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | MDM2, TP53, MDM4 | S1PR3 3894/4885CTSS 2469/4885CTSK 2125/4885 |
| US-20110060146-A1 | VITAMIN-D-LIKE COMPOUNDS | VDR, CYP24A1, CYP2R1 | S1PR3 250/4885CTSS 1416/4885CTSK 825/4885 |
| US-20230159538-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | S1PR3 1644/4885CTSS 4325/4885CTSK 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.